Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.

Abstract

Human papillomavirus (HPV)-related cancer is one of the diseases entities for which the applications of radiotherapy have been increasing. Recently, the process of carcinogenesis from HPV infection and the mechanism of tumor immunity that develops during disease progression have been elucidated. In this review, we will describe the mechanism of tumor immunity and how chemoradiotherapy may overcome and improve the efficacy of tumor immunity. We will also discuss the usefulness of proteins involved with tumor immunity as a predictive marker of radiotherapy response, and present an overview of ongoing clinical trials of combinations of immune checkpoint inhibitors and radiotherapy to demonstrate the promising combination therapy that has been currently emerging.

• Authors: Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata
• Journal: Japanese journal of radiology (Jpn J Radiol) Vol. 40 Issue 5 Pg. 458-465 (May 2022) ISSN: 1867-108X [Electronic] Japan
• PMID: 34973113 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s).

Topics

• Alphapapillomavirus
• Female
• Humans
• Neoplasms (radiotherapy)
• Papillomaviridae
• Papillomavirus Infections (complications, drug therapy)
• Radioimmunotherapy
• Uterine Cervical Neoplasms